Category

News

ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease

By | News

ProMIS™ Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease Narrated presentation of results available on ProMIS website TORONTO,…

Read More

ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference

By | News, Uncategorized

ProMIS Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference Presentation highlights the use ProMIS’ proprietary discovery platform to identify novel therapeutic targets on misfolded…

Read More

ProMIS Neurosciences Independent Director Anthony J. Giovinazzo Recognized with Inaugural Bloom Burton Award for Innovation in Canadian Healthcare

By | News

ProMISTM Neurosciences, Inc. NEWS RELEASE TSX: PMN FOR IMMEDIATE RELEASE ProMIS Neurosciences Independent Director Anthony J. Giovinazzo Recognized with Inaugural Bloom Burton Award for Innovation in Canadian Healthcare TORONTO, ONTARIO and CAMBRIDGE, MA – September 21, 2017 – ProMIS Neurosciences, Inc.,…

Read More